Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 11/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3275648 | 1.00 | S1PR1 (0.42) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL3276734 | 1.00 | S1PR1 (0.42) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL3275227 | 0.93 | S1PR1 (0.47) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL3277916 | 0.93 | S1PR1 (0.47) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL3275230 | 0.93 | S1PR1 (0.47) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL3283656 | 0.89 | S1PR1 (0.53) | S1PR1S1PR3TSHRMEN1KMT2A | |
| SCHEMBL3283666 | 0.89 | S1PR1 (0.53) | S1PR1S1PR3TSHRMEN1KMT2A | |
| SCHEMBL3276772 | 0.86 | S1PR1 (0.60) | S1PR1S1PR3 | |
| SCHEMBL3276916 | 0.86 | S1PR1 (0.60) | S1PR1S1PR3 | |
| SCHEMBL3276776 | 0.86 | S1PR1 (0.60) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125797-B1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-15 | — | — | EP | claimed |
| US-8592460-B2 | Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-26 | — | — | US | claimed |
| US-20100087417-A1 | AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-08 | — | — | US | claimed |
| EP-2125797-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | claimed |
| WO-2008114157-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-25 | — | — | WO | claimed |
| EP-2125797-B1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-8592460-B2 | Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20100087417-A1 | AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-2125797-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008114157-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087417-A1 | AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR4 | S1PR1 1/4885S1PR3 2/4885MAP4K4 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.